标题
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
作者
关键词
-
出版物
NEW ENGLAND JOURNAL OF MEDICINE
Volume -, Issue -, Pages -
出版商
Massachusetts Medical Society
发表日期
2023-06-05
DOI
10.1056/nejmoa2303379
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
- (2023) Paula Rodriguez-Otero et al. NEW ENGLAND JOURNAL OF MEDICINE
- CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma.
- (2023) Yi Lin et al. JOURNAL OF CLINICAL ONCOLOGY
- VP5-2022: Updated progression-free survival (PFS) and depth of response in IKEMA, a randomized phase III trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) vs Kd in relapsed multiple myeloma (MM)
- (2022) P. Moreau et al. ANNALS OF ONCOLOGY
- Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies
- (2022) Adam D. Cohen et al. Blood Cancer Journal
- Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
- (2022) Thomas Martin et al. JOURNAL OF CLINICAL ONCOLOGY
- P-240: Real-world assessment of treatment patterns and outcomes in patients with lenalidomide-refractory relapsed multiple myeloma from the SEER-Medicare database
- (2022) Binod Dhakal et al. Clinical Lymphoma Myeloma & Leukemia
- Ciltacabtagene Autoleucel (Cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients with Multiple Myeloma (MM) and Early Relapse after Initial Therapy: CARTITUDE-2 Cohort B 18-Month Follow-up
- (2022) Niels WCJ Van De Donk et al. BLOOD
- How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma
- (2022) Felipe de Arriba de la Fuente et al. Cancers
- Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial
- (2021) Philippe Moreau et al. LANCET
- Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
- (2021) Jesus G Berdeja et al. LANCET
- Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial
- (2021) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- Real‐world data on survival improvement in patients with multiple myeloma treated at a single institution over a 45‐year period
- (2021) Luis Gerardo Rodríguez‐Lobato et al. BRITISH JOURNAL OF HAEMATOLOGY
- Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study
- (2021) Saad Z Usmani et al. LANCET ONCOLOGY
- Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
- (2020) Meletios Dimopoulos et al. LANCET
- Sequencing multiple myeloma therapies with and after antibody therapies
- (2020) Niels W. C. J. van de Donk Hematology-American Society of Hematology Education Program
- Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
- (2019) Paul G Richardson et al. LANCET ONCOLOGY
- ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells
- (2018) Daniel W Lee et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting
- (2018) Paul G. Richardson et al. Blood Cancer Journal
- Multiple myeloma: patient outcomes in real-world practice
- (2016) Kwee Yong et al. BRITISH JOURNAL OF HAEMATOLOGY
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
- (2016) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Designing therapeutic cancer vaccine trials with delayed treatment effect
- (2016) Zhenzhen Xu et al. STATISTICS IN MEDICINE
- Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
- (2011) S. V. Rajkumar et al. BLOOD
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search